Michael K.
- Country
- Germany
- Department
- III. Medizinische Klinik und Poliklinik
Research Overview
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- Phase III Randomized Study of CPX-351 Versus Standard Chemotherapy in Adults with Newly Diagnosed AML and Intermediate or Adverse Genetic Risk
Data & Insights
Has run more than one trial at 145 of 282 partner sites.
Specializations
Acute Myeloid Leukemia Management
This investigator specializes in treating acute myeloid leukemia (AML), with particular emphasis on both newly diagnosed cases and those with relapsed/refractory disease. Their research encompasses innovative therapeutic approaches for patients with specific genetic mutations, including NPM1 mutations and KMT2A rearrangements.
- Newly diagnosed AML treatment strategies
- Relapsed/refractory AML management
- Genetic mutation-specific therapies
Novel Therapeutic Compounds
The investigator focuses on evaluating cutting-edge treatments including menin-MLL inhibitors and venetoclax-based combinations. Their work includes assessment of innovative drug combinations and novel therapeutic approaches for patients who are not eligible for intensive chemotherapy.
- Targeted molecular therapies
- Combination treatment strategies
- Alternative approaches to intensive chemotherapy
Hematologic Malignancies
The investigator's expertise extends to various hematologic conditions, including myelodysplastic syndrome with excess blasts and different forms of acute leukemias. Their research encompasses both standard intensive chemotherapy and novel therapeutic approaches.
- Treatment of high-risk leukemias
- Management of myelodysplastic syndromes
- Risk-adapted therapeutic strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.